KRYS
Krystal Biotech
$313.66
+$2.15 (+0.69%)Oct 26, 2026
Key metrics
The numbers that frame KRYS today
- Market cap
- $9.28B
- P/E (TTM)
- 39.3
- EV / FCF
- 34.4
- Gross margin
- 94.6%
- EV / Sales
- 20.1
- ROIC
- 27.8%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $183.26
- 52wk High
- $382.54
Growth
Revenue and earnings trend for KRYS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about KRYS
Is Krystal Biotech a good buy?
Yes. Krystal Biotech has excellent quality and excellent momentum. Both signals support the setup. Growth looks weak, a caveat that does not overturn the setup. We think Krystal Biotech is selling at a fair price.
What is the market capitalization of KRYS?
Krystal Biotech's market capitalization is $9.28B.
What is the P/E (TTM) ratio for KRYS stock?
Krystal Biotech's P/E (TTM) ratio is 39.3, based on trailing earnings.
What is the 52-week high for KRYS stock?
The 52-week high for Krystal Biotech is $382.54. The current close of $313.66 is 18% below that high.
What is the 52-week low for KRYS stock?
The 52-week low for Krystal Biotech is $183.26. The current close of $313.66 is 71.2% above that low.
Does KRYS stock pay dividends?
Krystal Biotech does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for KRYS?
Krystal Biotech's Debt / Equity ratio is 0.01.